Several other promising targets in the HER2 subtype of breast cancer such as HER3, GRPR, and vitamin B12 offer additional options for targeted therapy, with their respective companion diagnostic imaging agents readily available for assessing target engagement or monitoring response to treatment. The gene discussed is GRPR; the disease is breast carcinoma.